Drug2nd line2 diseases

Canakinumab

Anti–IL-1β monoclonal antibody

Response rate
High (RCT confirmed)
Onset
Days–weeks
Route
SC 150mg every 4–8 weeks
Line
2nd
IgM effect
No effect
Evidence level
amber

Used across diseases

DiseaseResponse rateLineEvidence
Schnitzler SyndromeHigh (RCT confirmed)2ndamber
Cryopyrin-Associated Periodic Syndromes78-97% complete response1stgreen

Evidence summary

Directly neutralises IL-1β with long half-life. The only RCT in Schnitzler demonstrated sustained efficacy.

Molecular targets

MoleculeRoleExpressionEvidence
IL-1βCentral pathogenic driverElevatedestablished

Sources (2)

H1de Koning HD et al. (2013) Canakinumab efficacy (9-month trial)DOI ↗
B2de Koning HD et al. (2015) IL-1β centrality via canakinumab trialDOI ↗